In recent years, there has been a surge of interest in tumor microenvironment-associated
cancer vaccine therapies. These innovative treatments aim to activate and enhance the …

Oncolytic viruses (OVs) as one promising antitumor methods have made important
contributions to tumor immunotherapy, which arouse increasing attention. They provide the …

Background Pediatric patients with diffuse intrinsic pontine glioma (DIPG) have a poor
prognosis, with a median survival of less than 1 year. Oncolytic viral therapy has been …

Substitution of lysine 27 to methionine in histone H3 (H3K27M) defines an aggressive
subtype of diffuse glioma. Previous studies have shown that a H3K27M-specific long peptide …

Diffuse intrinsic pontine glioma (DIPG) is an aggressive brain stem tumor and the leading
cause of pediatric cancer-related death. To date, these tumors remain incurable …

Diffuse intrinsic pontine glioma (DIPG) is an incurable malignant childhood brain tumor, with
no active systemic therapies and a 5-year survival of less than 1%. Polyamines are small …

Fusion oncogenes (FOs) are common in many cancer types and are powerful drivers of
tumor development. Because their expression is exclusive to cancer cells and their …

Glioblastoma is the most aggressive form of malignant brain tumor. Standard treatment
protocols and traditional immunotherapy are poorly effective as they do not significantly …

Immunotherapy has moved to the forefront of modern oncologic treatment in the past few
decades. Various forms of immunotherapy currently are emerging, including oncolytic …

It has been well established that mutations in the tumor suppressor gene, p53, occur readily
in a vast majority of cancer tumors, including ovarian cancer. Typically diagnosed in stages …